The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD

Inhaled corticosteroid/long-acting β(2)-agonist combination therapy is recommended in chronic obstructive pulmonary disease (COPD) patients at high risk of exacerbations. The EFFECT (Efficacy of Fluticasone propionate/FormotErol in COPD Treatment) trial is a Phase III, 52-week, randomized, double-bl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Chron Obstruct Pulmon Dis
Autors principals: Papi, Alberto, Jones, Paul W, Dalvi, Prashant S, McAulay, Kirsten, McIver, Tammy, Dissanayake, Sanjeeva
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2015
Matèries:
Methodology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648608/
https://ncbi.nlm.nih.gov/pubmed/26648706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S93375
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars